ASCO GUIDELINES Bundle

Metastatic HER2-Negative Breast Cancer – Chemo and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475478

Contents of this Issue

Navigation

Page 7 of 7

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2022 All rights reserved Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/breast- cancer-guidelines. Copyright © 2022 by American Society of Clinical Oncolog y. All rights reserved. ASCOMOY7224b Source Moy B, Rumble R, Come S et al. Chemotherapy and Targeted erapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer at is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022 August 4. doi: 10.1200/JCO.22.01533 Moy B, Rumble R, Come S et al. Chemotherapy and Targeted erapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer at is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. J Clin Oncol. 2021;39(35):3938-3958. doi:10.1200/jco.21.01374. ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/breast-cancer-guidelines. Abbreviations BRCA, BReast CAncer gene; HER2, human epidermal growth factor receptor2; HR, hormone receptor; OS, overall survival; PARP, poly-ribose polymerase Recommendation Grading Type Benefit/harm Evidence Quality Strength of Recommendation EB Evidence-based B Benefits outweigh harms H High Strong CB/ FC Consensus- based/Formal Consensus H Harms outweigh benefits I Intermediate Moderate IC Informal consensus B/H Relative balance of benefits and harms L Low Weak N No recommendation U Benefits/harms ratio uncertain Ins Insufficient

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Metastatic HER2-Negative Breast Cancer – Chemo and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative